Executive Committee

Print

This group directs The Biomarkers Consortium and is composed of the founding partners and other stakeholders.  Approved projects receive the attention of consortium fundraising activities within the Foundation for NIH.

Charles A. Sanders, M.D. (Chairman, The Biomarkers Consortium Executive Committee)
Chairman, Foundation for NIH

ShaAvhrée Yvette Buckman, M.D., Ph.D., F.A.A.P
Director, Office of Translational Sciences
Food and Drug Administration 

Stephen Eck, M.D., Ph.D. (representative:  pharmaceutical/biotechnology industries)
Vice President, Translational Medicine & Pharmacogenomics
Eli Lilly and Company

Gary Herman, M.D. (representative:  pharmaceutical/biotechnology industries)
Vice President, Early Stage Development (ESD)
Merck Research Laboratories

Thomas Insel, M.D.
Director
National Institute of Mental Health

Garry Neil, M.D. (representative:  pharmaceutical/biotechnology industries)
Corporate Vice President, Corporate Office of Science and Technology (COSAT)
Johnson & Johnson
 

John Niederhuber, M.D.
Director
National Cancer Institute

Steven Paul, M.D. (representative:  Foundation for the National Institutes of Health)
Board Member, Foundation for NIH
Executive Vice President, Science and Technology
President, Lilly Research Laboratories
Eli Lilly and Company

Sara Radcliffe, M.P.H. (temporary representative: diagnostics, information technology, and other industrial sectors)
Vice President, Scientific and Regulatory Affairs
Biotechnology Industry Organization

Ellen V. Sigal, Ph.D. (representative:  Foundation for the National Institutes of Health)
Board Member, Foundation for NIH
Chairperson
Friends of Cancer Research

Barry M. Straube, M.D.
Chief Medical Officer
Director, Office of Clinical Standards and Quality
Centers for Medicare and Medicaid Services

Lawrence Tabak, D.D.S., Ph.D.
Director
National Institute of Dental and Craniofacial Research

Janet Woodcock, M.D.
Director, Center for Drug Evaluation and Research
Food and Drug Administration 

Mary Woolley, M.A. (public representative)
President and Chief Executive Officer
Research!America

 

  • About Biomarkers

    Biomarkers are characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to therapeutic intervention. More

  • Join Us

    Become a Member
    Learn how you can join and support The Biomarkers Consortium.

    The Biomarkers Consortium embraces government, industry, patient advocacy groups, and non-profit organizations, each of which has a stake in the development of biomarker technology.

  • Latest News

    THE BIOMARKERS CONSORTIUM LAUNCHES I-SPY 2 BREAST CANCER CLINICAL TRIAL:  Click here to read the press release.

    March 17, 2010 -- Announcing the launch of the Biomarkers Consortium I-SPY 2 TRIAL (Investigation of Serial studies to Predict Your Therapeutic Response with Imaging and moLecular analysis): An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy), which is taking place today from 9-10:30 a.m. ET at the National Press Club, Washington, DC.  Click here for more information.

    View the Web Cast

     

    Six awardees conducting data analysis to Develop Clinical Criteria for the Diagnosis of Clinically Important Weakness Associated with Low Muscle Mass in Older Adults: Click here to read

    The Metabolic Disorders Steering Committee releases strategy for Mathematical Modeling in Atherosclerosis:  Details

    PRESS RELEASE:  The Biomarkers Consortium Completes First Project to Show That Adiponectin is a Predictive Biomarker for Type 2 Diabetes:  Click here to read

    RFP for Data Analysis to Develop Clinical Criteria for the Diagnosis of Clinically Important Weakness Associated with Low Muscle Mass in Older Adults.  Due Date: September 8, 2009.  Click here to read.

     

    Available Now: The Biomarkers Consortium Report, Volume 1, Issue 1, May 2009. Click Here to Read

    The Metabolic Disorders Steering Committee Prioritized Areas of Unmet Need: As advertised in Volume 58, No. 4, April 2009 issue of Diabetes.  Click Here to read.

    Presentations Available from the Beta Cell Function Symposium. Click here for agenda.